688321 微芯生物
已收盘 10-29 15:00:00
资讯
新帖
简况
微芯生物（688321）10月28日主力资金净卖出2038.33万元
证券之星 · 10-29 08:46
微芯生物（688321）10月28日主力资金净卖出2038.33万元
图解微芯生物三季报：第三季度单季净利润同比下降51.93%
证券之星 · 10-28 01:08
图解微芯生物三季报：第三季度单季净利润同比下降51.93%
微芯生物(688321.SH)发布前三季度业绩，归母净利润9117万元，同比增长28.84%
智通财经 · 10-27 20:53
微芯生物(688321.SH)发布前三季度业绩，归母净利润9117万元，同比增长28.84%
微芯生物(688321)9月30日股东户数2.69万户，较上期增加5.34%
证券之星 · 10-27 18:36
微芯生物(688321)9月30日股东户数2.69万户，较上期增加5.34%
股市必读：微芯生物新发布《关于召开2026年第三季度业绩说明会的公告》
证券之星 · 10-22
股市必读：微芯生物新发布《关于召开2026年第三季度业绩说明会的公告》
微芯生物最新公告：签订NW001项目合作开发协议
证券之星 · 10-21
微芯生物最新公告：签订NW001项目合作开发协议
微芯生物：拟与参股公司合作开发NW001项目 涉关联交易
格隆汇 · 10-21
微芯生物：拟与参股公司合作开发NW001项目 涉关联交易
微芯生物（688321）披露2026年第三季度业绩说明会公告，10月20日股价上涨2.71%
证券之星 · 10-20
微芯生物（688321）披露2026年第三季度业绩说明会公告，10月20日股价上涨2.71%
股市必读：微芯生物新发布《自愿披露关于NW001获得药物临床试验批准通知书的公告》
证券之星 · 10-19
股市必读：微芯生物新发布《自愿披露关于NW001获得药物临床试验批准通知书的公告》
微芯生物：NW001获得药物临床试验批准
格隆汇 · 10-16
微芯生物：NW001获得药物临床试验批准
股市必读：微芯生物新发布《自愿披露关于CS23546片临床试验申请获得受理的公告》
证券之星 · 10-16
股市必读：微芯生物新发布《自愿披露关于CS23546片临床试验申请获得受理的公告》
微芯生物最新公告：CS23546片临床试验申请获受理
证券之星 · 10-14
微芯生物最新公告：CS23546片临床试验申请获受理
10月14日微芯生物创60日新低，建信中证1000指数增强A基金重仓该股
证券之星 · 10-14
10月14日微芯生物创60日新低，建信中证1000指数增强A基金重仓该股
微芯生物（688321）10月13日主力资金净卖出401.92万元
证券之星 · 10-14
微芯生物（688321）10月13日主力资金净卖出401.92万元
微芯生物最新公告：CS43158片获药物临床试验批准通知书
证券之星 · 10-12
微芯生物最新公告：CS43158片获药物临床试验批准通知书
股市必读：微芯生物新发布《关于可转债转股结果暨股份变动的公告》
证券之星 · 10-12
股市必读：微芯生物新发布《关于可转债转股结果暨股份变动的公告》
微芯生物（688321）披露可转债转股结果暨股份变动公告，10月08日股价下跌4.6%
证券之星 · 10-08
微芯生物（688321）披露可转债转股结果暨股份变动公告，10月08日股价下跌4.6%
每周股票复盘：微芯生物（688321）半年报营收增33.60%
证券之星 · 09-13
每周股票复盘：微芯生物（688321）半年报营收增33.60%
股市必读：微芯生物新发布《国投证券股份有限公司关于深圳微芯生物科技股份有限公司2026年半年度持续督导跟踪报告》
证券之星 · 09-10
股市必读：微芯生物新发布《国投证券股份有限公司关于深圳微芯生物科技股份有限公司2026年半年度持续督导跟踪报告》
每周股票复盘：机构净卖出微芯生物（688321）1112.09万元
证券之星 · 09-06
每周股票复盘：机构净卖出微芯生物（688321）1112.09万元
加载更多
公司概况
公司名称：
深圳微芯生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2019-08-12
主营业务：
深圳微芯生物科技股份有限公司的主营业务是药物技术开发、相关成果商业应用；新药研究、开发、技术转让及其它有关的服务；新治疗技术研究、开发、技术转让及其它有关的服务；对外专利、技术的许可授权；药品的生产；保健食品生产经营。公司的主要产品是西达本胺、西格列他钠、西奥罗尼、CS23546、CS231295、CS32582、CS08399、CS43158、NW001、CS12088、CS12192。公司是国家级专精特新“小巨人”企业。
发行价格：
20.43
{"stockData":{"symbol":"688321","market":"SH","secType":"STK","nameCN":"微芯生物","latestPrice":20.15,"timestamp":1793257200000,"preClose":20.55,"halted":0,"volume":8226868,"delay":0,"changeRate":-0.0195,"floatShares":443000000,"shares":443000000,"eps":0.1612,"marketStatus":"已收盘","change":-0.4,"latestTime":"10-29 15:00:00","open":20.33,"high":20.44,"low":19.77,"amount":165000000,"amplitude":0.0326,"askPrice":20.16,"askSize":315,"bidPrice":20.15,"bidSize":18,"shortable":0,"etf":0,"ttmEps":0.1612,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793323800000},"marketStatusCode":5,"adr":0,"adjPreClose":20.55,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793237400000,1793244600000],[1793250000000,1793257200000]],"highLimit":22.61,"lowLimit":18.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":442941642,"isCdr":false,"pbRate":3.67,"roa":"--","peRate":125,"roe":"3.87%","epsLYR":0.125,"committee":-0.384929,"marketValue":8925000000,"turnoverRate":0.0186,"status":1,"afterMarket":{"amount":40803.75,"volume":2025,"close":20.15,"buyVolume":2444,"sellVolume":0,"time":1793259237746,"indexStatus":"已收盘 10-29 15:30:00","preClose":20.55},"floatMarketCap":8925000000},"requestUrl":"/m/hq/s/688321","defaultTab":"news","newsList":[{"id":"2679460654","title":"微芯生物（688321）10月28日主力资金净卖出2038.33万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679460654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679460654?lang=zh_cn&edition=full","pubTime":"2026-10-29 08:46","pubTimestamp":1793234808,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月28日收盘，微芯生物报收于20.55元，下跌4.51%，换手率2.96%，成交量13.09万手，成交额2.67亿元。近5日资金流向一览见下表：微芯生物融资融券信息显示，融资方面，当日融资买入2487.47万元，融资偿还2579.26万元，融资净偿还91.79万元。微芯生物主营业务：为患者提供可承受的、临床亟需的原创新分子实体药物,具备完整的从药物作用靶点发现与确证、先导分子的发现与评价到新药临床开发、产业化、学术推广及销售的能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900015137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678040661","title":"图解微芯生物三季报：第三季度单季净利润同比下降51.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678040661","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678040661?lang=zh_cn&edition=full","pubTime":"2026-10-28 01:08","pubTimestamp":1793120905,"startTime":"0","endTime":"0","summary":"证券之星消息，微芯生物2026年三季报显示，前三季度公司主营收入8.41亿元，同比上升24.68%；归母净利润9117.49万元，同比上升28.84%；扣非净利润7909.02万元，同比上升35.34%；其中2026年第三季度，公司单季度主营收入2.97亿元，同比上升11.11%；单季度归母净利润1979.43万元，同比下降51.93%；单季度扣非净利润1438.84万元，同比下降62.25%；负债率43.16%，投资收益-1891.55万元，财务费用2885.45万元，毛利率86.55%。财报数据概要请见下图:本文数据来源于微芯生物2026年三季报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800002559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678170681","title":"微芯生物(688321.SH)发布前三季度业绩，归母净利润9117万元，同比增长28.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678170681","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678170681?lang=zh_cn&edition=full","pubTime":"2026-10-27 20:53","pubTimestamp":1793105613,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物(688321.SH)披露2026年第三季度报告，前三季度公司实现营业收入8.41亿元，同比增长24.67%;归母净利润9117万元，同比增长28.84%;扣非净利润7909万元，同比增长35.34%;基本每股收益0.2093元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678263173","title":"微芯生物(688321)9月30日股东户数2.69万户，较上期增加5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678263173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678263173?lang=zh_cn&edition=full","pubTime":"2026-10-27 18:36","pubTimestamp":1793097391,"startTime":"0","endTime":"0","summary":"证券之星消息，近日微芯生物披露，截至2026年9月30日公司股东户数为2.69万户，较6月30日增加1366.0户，增幅为5.34%。在化学制药行业个股中，微芯生物股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.84万户。从股价来看，2026年6月30日至2026年9月30日，微芯生物区间跌幅为4.22%，在此期间股东户数增加1366.0户，增幅为5.34%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700034502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677360199","title":"股市必读：微芯生物新发布《关于召开2026年第三季度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677360199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677360199?lang=zh_cn&edition=full","pubTime":"2026-10-22 03:25","pubTimestamp":1792610722,"startTime":"0","endTime":"0","summary":"公司公告汇总：微芯生物将于10月28日召开2026年第三季度业绩说明会，董事长XIANPING LU博士等高管将出席。公司公告汇总关于召开2026年第三季度业绩说明会的公告深圳微芯生物科技股份有限公司将于2026年10月28日10:00–11:00通过上证路演中心网络互动方式召开2026年第三季度业绩说明会，介绍公司经营成果和财务状况。NW001为表观免疫偶联药物，其IND申请已于2026年10月16日获国家药监局药审中心批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200003264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677208576","title":"微芯生物最新公告：签订NW001项目合作开发协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2677208576","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677208576?lang=zh_cn&edition=full","pubTime":"2026-10-21 18:05","pubTimestamp":1792577126,"startTime":"0","endTime":"0","summary":"微芯生物(688321.SH)公告称，公司及全资子公司成都微芯拟与参股公司微芯新域就NW001项目签订合作开发协议。公司将分阶段向微芯新域支付合计3000万元研发里程碑款及一定比例收益分配。NW001临床试验申请已于2026年10月16日获国家药监局药审中心批准。本次交易构成关联交易，已获董事会审议通过。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100031327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677627974","title":"微芯生物：拟与参股公司合作开发NW001项目 涉关联交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2677627974","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677627974?lang=zh_cn&edition=full","pubTime":"2026-10-21 18:00","pubTimestamp":1792576843,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676469469","title":"微芯生物（688321）披露2026年第三季度业绩说明会公告，10月20日股价上涨2.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676469469","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676469469?lang=zh_cn&edition=full","pubTime":"2026-10-20 22:24","pubTimestamp":1792506262,"startTime":"0","endTime":"0","summary":"截至2026年10月20日收盘，微芯生物报收于22.38元，较前一交易日上涨2.71%，最新总市值为99.13亿元。该股当日开盘21.8元，最高22.45元，最低21.57元，成交额达1.23亿元，换手率为1.25%。公告显示，公司将于2026年10月28日10:00-11:00通过上证路演中心网络互动方式召开2026年第三季度业绩说明会，介绍公司经营成果和财务状况。投资者可于2026年10月21日至10月27日16:00前通过上证路演中心网站或公司邮箱ir@chipscreen.com提交问题。说明会结束后可通过该平台查看会议内容。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000036908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676157805","title":"股市必读：微芯生物新发布《自愿披露关于NW001获得药物临床试验批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676157805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676157805?lang=zh_cn&edition=full","pubTime":"2026-10-19 02:22","pubTimestamp":1792347730,"startTime":"0","endTime":"0","summary":"公司公告汇总：微芯生物收到《药物临床试验批准通知书》，NW001获准开展治疗晚期恶性肿瘤的临床试验。公司公告汇总自愿披露关于NW001获得药物临床试验批准通知书的公告深圳微芯生物科技股份有限公司收到国家药监局签发的《药物临床试验批准通知书》，其与成都微芯新域生物技术有限公司合作研发的注射用NW001获准开展治疗晚期恶性肿瘤的临床试验。该药有望提升PD-L1单抗疗效，并克服免疫耐药问题。药品尚需开展临床试验，获批上市存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900000715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675915495","title":"微芯生物：NW001获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2675915495","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675915495?lang=zh_cn&edition=full","pubTime":"2026-10-16 19:41","pubTimestamp":1792150893,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675914532","title":"股市必读：微芯生物新发布《自愿披露关于CS23546片临床试验申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675914532","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675914532?lang=zh_cn&edition=full","pubTime":"2026-10-16 03:06","pubTimestamp":1792091173,"startTime":"0","endTime":"0","summary":"公司公告汇总：CS23546片联合治疗复发/难治性淋巴瘤的临床试验申请获国家药监局药审中心受理。公司公告汇总自愿披露关于CS23546片临床试验申请获得受理的公告深圳微芯生物科技股份有限公司近日收到国家药品监督管理局药物审评中心签发的《受理通知书》，其自主研发的CS23546片用于联合治疗复发/难治性淋巴瘤的新药临床试验申请已获受理。CS23546为口服PD-L1小分子抑制剂，属化药1类新药，具有良好的肿瘤渗透性和组织选择性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600002640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675345840","title":"微芯生物最新公告：CS23546片临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2675345840","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675345840?lang=zh_cn&edition=full","pubTime":"2026-10-14 18:39","pubTimestamp":1791974381,"startTime":"0","endTime":"0","summary":"微芯生物公告称，公司近日收到国家药监局药审中心签发的《受理通知书》，自主研发的CS23546片关于联合治疗复发/难治性淋巴瘤的临床试验申请获得受理。CS23546是公司自主研发的口服PD-L1小分子抑制剂，属于化药1类新药。本次申请为新药临床试验申请，自受理之日起60日内未收到否定或质疑意见的，公司可按提交方案开展临床试验，但临床试验能否最终开展存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400033431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675131440","title":"10月14日微芯生物创60日新低，建信中证1000指数增强A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675131440","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675131440?lang=zh_cn&edition=full","pubTime":"2026-10-14 16:29","pubTimestamp":1791966596,"startTime":"0","endTime":"0","summary":"证券之星消息，10月14日微芯生物创60日新低，收盘报21.96元，当日跌3.68%，换手率1.43%，成交量6.33万手，成交额1.41亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为建信基金的建信中证1000指数增强A。建信中证1000指数增强A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400027566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0144","BK0010","BK0012","BK0028","BK0176","BK0239","BK0005","688321","BK0251","BK0164","000852","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675205395","title":"微芯生物（688321）10月13日主力资金净卖出401.92万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675205395","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675205395?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:25","pubTimestamp":1791937545,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，微芯生物报收于22.8元，下跌3.47%，换手率1.98%，成交量8.75万手，成交额1.99亿元。近5日资金流向一览见下表：微芯生物融资融券信息显示，融资方面，当日融资买入2974.33万元，融资偿还2138.78万元，融资净买入835.55万元。微芯生物主营业务：为患者提供可承受的、临床亟需的原创新分子实体药物,具备完整的从药物作用靶点发现与确证、先导分子的发现与评价到新药临床开发、产业化、学术推广及销售的能力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674981877","title":"微芯生物最新公告：CS43158片获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2674981877","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674981877?lang=zh_cn&edition=full","pubTime":"2026-10-12 20:00","pubTimestamp":1791806406,"startTime":"0","endTime":"0","summary":"微芯生物(688321.SH)公告称，公司近日收到国家药监局签发的《药物临床试验批准通知书》，同意公司产品CS43158片开展急性髓系白血病的临床试验。该药是一款多靶点蛋白激酶抑制剂，可同时覆盖急性髓系白血病的驱动致癌通路与旁路激活耐药通路，兼具靶向原发驱动突变与克服继发耐药的双重作用。本次临床试验申请获批对公司近期业绩不会产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200030997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674084687","title":"股市必读：微芯生物新发布《关于可转债转股结果暨股份变动的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674084687","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674084687?lang=zh_cn&edition=full","pubTime":"2026-10-12 03:16","pubTimestamp":1791746172,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总：10月9日主力资金净流出435.15万元，占总成交额2.14%； 公司公告汇总：2026年7月1日至9月30日微芯转债累计转股355股，对应转债金额9,000元，占转股前总股本0.0001%。公司公告汇总关于可转债转股结果暨股份变动的公告深圳微芯生物科技股份有限公司公告，2026年7月1日至9月30日，微芯转债有9,000元转换为公司股票，转股数量为355股，占转股前总股本的0.0001%。期间因限售股上市流通及可转债转股，公司总股本由442,941,287股增至442,941,642股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200001042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673700393","title":"微芯生物（688321）披露可转债转股结果暨股份变动公告，10月08日股价下跌4.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673700393","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673700393?lang=zh_cn&edition=full","pubTime":"2026-10-08 22:17","pubTimestamp":1791469039,"startTime":"0","endTime":"0","summary":"截至2026年10月8日收盘，微芯生物报收于24.06元，较前一交易日下跌4.6%，最新总市值为106.57亿元。近日，深圳微芯生物科技股份有限公司披露《关于可转债转股结果暨股份变动的公告》。公告显示，2026年7月1日至9月30日，微芯转债有9,000元转换为公司股票，转股数量为355股，占转股前总股本的0.0001%。截至2026年9月30日，累计428,000元转债转换为16,904股，占转股前总股本的0.0041%。期间因限售股上市流通及可转债转股，公司总股本由442,941,287股增至442,941,642股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800034363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507188","title":"每周股票复盘：微芯生物（688321）半年报营收增33.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507188","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507188?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:17","pubTimestamp":1789237029,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，微芯生物报收于23.68元，较上周的25.18元下跌5.96%。本周，微芯生物9月7日盘中最高价报25.53元。来自公司公告汇总：2026年上半年微芯生物营业收入同比增长33.60%，净利润显著增长。交易信息汇总9月9日微芯生物发生1笔大宗交易，机构专用席位净卖出286.7万元。公司公告汇总国投证券股份有限公司发布关于深圳微芯生物科技股份有限公司2026年半年度持续督导跟踪报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666534466","title":"股市必读：微芯生物新发布《国投证券股份有限公司关于深圳微芯生物科技股份有限公司2026年半年度持续督导跟踪报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666534466?lang=zh_cn&edition=full","pubTime":"2026-09-10 01:07","pubTimestamp":1788973628,"startTime":"0","endTime":"0","summary":"公司公告汇总国投证券股份有限公司关于深圳微芯生物科技股份有限公司2026年半年度持续督导跟踪报告国投证券作为微芯生物2024年度向特定对象发行A股股票项目的保荐人，对2026年上半年持续督导情况进行报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000001818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665563366","title":"每周股票复盘：机构净卖出微芯生物（688321）1112.09万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665563366","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665563366?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:23","pubTimestamp":1788636189,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，微芯生物（688321）报收于25.18元，较上周的25.83元下跌2.52%。本周，微芯生物9月4日盘中最高价报25.75元。9月2日盘中最低价报24.82元。微芯生物当前最新总市值111.53亿元，在化学制药板块市值排名42/149，在两市A股市值排名1646/5214。本周关注点来自交易信息汇总：9月3日微芯生物现1笔大宗交易，机构净卖出1112.09万元交易信息汇总9月3日微芯生物现1笔大宗交易，机构净卖出1112.09万元以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600001127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793296752947,"stockEarnings":[{"period":"1week","weight":-0.0915},{"period":"1month","weight":-0.1914},{"period":"3month","weight":-0.2385},{"period":"6month","weight":-0.3554},{"period":"1year","weight":-0.3067},{"period":"ytd","weight":-0.3091}],"compareEarnings":[{"period":"1week","weight":-0.0018},{"period":"1month","weight":-0.0467},{"period":"3month","weight":-0.0472},{"period":"6month","weight":-0.112},{"period":"1year","weight":-0.0909},{"period":"ytd","weight":-0.08}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳微芯生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"26931人(较上一季度增加5.34%)","perCapita":"16447股","listingDate":"2019-08-12","address":"广东省深圳市南山区西丽街道曙光社区智谷产业园B栋21F-24F","registeredCapital":"44294万元","survey":" 深圳微芯生物科技股份有限公司的主营业务是药物技术开发、相关成果商业应用；新药研究、开发、技术转让及其它有关的服务；新治疗技术研究、开发、技术转让及其它有关的服务；对外专利、技术的许可授权；药品的生产；保健食品生产经营。公司的主要产品是西达本胺、西格列他钠、西奥罗尼、CS23546、CS231295、CS32582、CS08399、CS43158、NW001、CS12088、CS12192。公司是国家级专精特新“小巨人”企业。","listedPrice":20.43},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"微芯生物,688321,微芯生物股票,微芯生物股票老虎,微芯生物股票老虎国际,微芯生物行情,微芯生物股票行情,微芯生物股价,微芯生物股市,微芯生物股票价格,微芯生物股票交易,微芯生物股票购买,微芯生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}